Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 586 • 2013 ACR/ARHP Annual Meeting
Blood Pressure Variability and Age-Related Blood Pressure Patterns In Systemic Lupus Erythematosus
George Stojan¹, Laurence S. Magder² and Michelle Petri³, ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Increased visit-to-visit blood pressure (BP) variability has been associated with an increased risk of all-cause mortality, stroke, left ventricular diastolic dysfunction, and cognitive impairment…
Abstract Number: 597 • 2013 ACR/ARHP Annual Meeting
Low Complement (C3), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus
Adnan Kiani¹, Armin Zadeh², Jens Vogel-Claussen¹, Joao Lima², Laurence S. Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: New technology (CTA) can measure non-calcified coronary plaque (NCP), which is highly unstable and prone to rupture. We quantified NCP in SLE and determined…
Abstract Number: 574 • 2013 ACR/ARHP Annual Meeting
Oral Candidiasis in Systemic Lupus Erythematosus
Monthida Fangtham, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Candida is the most common opportunistic fungal infection identified in SLE. In a previous autopsy study, 14 percent of deaths in SLE patients were…
Abstract Number: 2899 • 2013 ACR/ARHP Annual Meeting
Outcome Of Incidental Silent Strokes In Systemic Lupus Erythematosus
Jamal Mikdashi, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Silent strokes are brain infarcts that lack clinically overt stroke-like symptoms and fail to come to clinical attention. The prevalence of incidentally detected acute/subacute…
Abstract Number: 2738 • 2013 ACR/ARHP Annual Meeting
Microrna-Mediated Regulation Explains Allelic Risk Of TLR7 Variant Predisposing To Systemic Lupus Erythematosis
Yun Deng¹, Jian Zhao¹, Jennifer M. Grossman² and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: We identified a genome-wide significant association of the TLR7 variant (rs3853839) with SLE susceptibility in multiple ancestries (Pmeta =2.0×10-19, OR =1.25), and the risk…
Abstract Number: 2505 • 2013 ACR/ARHP Annual Meeting
Higher Disease Damage Among African Americans With Familial Versus Sporadic Systemic Lupus Erythematosus
April Barnado¹, Lee Wheless², Stephanie Slan¹, Gary S. Gilkeson¹ and Diane L. Kamen¹, ¹Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Public Health Sciences, Medical University of South Carolina, Charleston, SC
Background/Purpose: Studies in predominantly Caucasian cohorts have found no significant clinical or serologic differences in systemic lupus erythematosus (SLE) patients with a family history of…
Abstract Number: 1583 • 2013 ACR/ARHP Annual Meeting
Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome
Mansour Somaily¹, Dafna D. Gladman², Dominique Ibanez² and Murray B. Urowitz², ¹Medicine, Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Serositis is one of the ACR classification criteria for SLE. Its incidence is variable in studies varying from 12 to 60%. The aim of…
Abstract Number: 1412 • 2012 ACR/ARHP Annual Meeting
Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Adnan Kiani¹, Hong Fang¹, Tianfu Wu², Chandra Mohan³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ³Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. High levels of VCAM-1 have been…
Abstract Number: 843 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects
Erin Zoller¹, Leah C. Kottyan², Bahram Namjou¹, Samuel Vaughn¹, Miranda C. Marion³, Carl D. Langefeld⁴, Marta E. Alarcon-Riquelme⁵, Juan-Manuel Anaya⁶, Elizabeth E. Brown on behalf of PROFILE⁷, Sang-Cheol Bae⁸, Jeffrey C. Edberg⁹, Patrick M. Gaffney¹⁰, Diane L. Kamen¹¹, Robert P. Kimberly¹², Chaim O. Jacob¹³, Joan T. Merrill¹⁴, Kathy Moser Sivils¹⁵, Michelle Petri¹⁶, Rosalind Ramsey-Goldman¹⁷, John D. Reveille¹⁸, Anne M. Stevens¹⁹, Betty P. Tsao²⁰, Luis M. Vila²¹, Timothy J. Vyse²² and Kenneth M. Kaufman²³, ¹Division of Rheumatology and The Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁶School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹²Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ¹⁹Pediatrics, University of Washington, Seattle, WA, ²⁰Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²²Medical & Molecular Genetics, King's College London, London, United Kingdom, ²³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH
Background/Purpose: Powerful evidence suggests that Systemic lupus erythematous (SLE or lupus) autoimmunity is mediated by disregulation of the IRF5-NFκB signaling pathway. The interferon regulatory factor 5…
Abstract Number: 1387 • 2012 ACR/ARHP Annual Meeting
Hospitalizations and Reasons for Admission in a Clinical SLE Cohort
Alaa Dekis¹, Kenjey Chan¹, Christian A. Pineau², Evelyne Vinet³, Emil P. Nashi², Sasha Bernatsky⁴ and Ann E. Clarke⁴, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Center, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Data published from several countries have suggested that patients affected by systemic lupus erythematous (SLE) may have high annual hospitalization rates. However, there is…
Abstract Number: 845 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells
Niklas Hagberg¹, Jakob Theorell², Gunnar V. Alm³, Maija-Leena Eloranta⁴, Yenan Bryceson² and Lars Rönnblom⁴, ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden
Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by…
Abstract Number: 1393 • 2012 ACR/ARHP Annual Meeting
Predictors of Panniculitis in Systemic Lupus Erythematosus
Ashika Odhav¹, Michelle Petri² and Hong Fang², ¹University of Missouri Kansas City School of Medicine, Kansas, MO, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Panniculitis is a rare, but devastating manifestation of SLE. We examined associates of panniculitis in a large SLE cohort. Methods: 52 out of 2,149…
Abstract Number: 663 • 2012 ACR/ARHP Annual Meeting
The Clinical Significance and Expression of P2X7 Purinergic Receptor in Peripheral Blood from Patients with New-Oneset Systemic Lupus Erythematosus
Xiangpei Li¹, Meiyun Wang², Jinhui Tao², Xiaomei Li² and Ning Yu¹, ¹Department of Rheumatology and Immunology,, Anhui Medical University Affiliated Provincial Hospital, Hefei, Anhui, China, ²Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, Hefei, Anhui, China
Background/Purpose: P2X7 purinergic receptor (P2X7R) is encoded by a gene within the human SLE locus SLEB4. Extracellular adenosine triphosphate (ATP) regulates inflammatory cells by activation…
Abstract Number: 1395 • 2012 ACR/ARHP Annual Meeting
The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Majed M. Khraishi¹, Rana Aslanov² and Krista Fudge³, ¹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada, ³Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada
Background/Purpose: SLE is a chronic autoimmune disease with variable manifestations. New developments in the understanding and treatment of SLE mandated closer monitoring of the disease…
Abstract Number: 633 • 2012 ACR/ARHP Annual Meeting
Missed Work Days in Systemic Lupus Erythematosus
Jie Xu¹, Hong Fang² and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Indirect costs are part of the medical and financial burden of SLE. These costs are easy to undervalue because a significant portion of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].